Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

LLS30

Copy Product Info
🥰Excellent

Synonyms:

Catalog No. T69874 Copy Product Info
🥰Excellent
LLS30 is an allosteric inhibitor of Galectin-1 (Gal-1). LLS30 inhibits the downstream MEK/ERK signaling pathway and also inhibits Akt phosphorylation. LLS30 exhibits potent proliferation-inhibitory activity against various prostate cancer cell lines.
LLS30
Cas No. 2138367-58-3
Pack SizePriceUSA StockGlobal StockQuantity
25 mg$2,500-In Stock
50 mg$3,850-In Stock
100 mg$6,150-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:>99.99%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
LLS30 is an allosteric inhibitor of Galectin-1 (Gal-1). LLS30 inhibits the downstream MEK/ERK signaling pathway and also inhibits Akt phosphorylation. LLS30 exhibits potent proliferation-inhibitory activity against various prostate cancer cell lines.
In vitro
Methods: NF96.2 and NF02.2 cells were treated with LLS30 at various concentrations (0, 1.5, 3, 10, 20, 50, 100 μM) for 72 hours, and cell viability was assessed using the MTT assay.
Results: LLS30 inhibited proliferation in a dose-dependent manner, with IC₅₀ values of 2.9 μM and 3.6 μM for NF96.2 and NF02.2, respectively. [1]
Methods: NF96.2 and NF02.2 cells were treated with 5 μM LLS30 for 12 and 24 hours, and caspase-3/7 activity was detected.
Results: LLS30 significantly increased caspase-3/7 activity and induced MPNST cell apoptosis in a time-dependent manner. [1]
Methods: PC3, DU145, 22RV1, and CWR-R1 cells were seeded at 3 × 10³ cells per well and treated with (1, 5, 10, 25, 50, 100 μM) LLS30 for 72 h; cell viability was assessed using the CellTiter-Glo assay.
Results: LLS30 inhibited CRPC cell proliferation in a dose-dependent manner, with IC₅₀ values of 10.4 μM for PC3, 5.3 μM for DU145, 3.3 μM for 22RV1, and 5.9 μM for CWR-R1.[2]
In vivo
Methods: An in situ tumor model was established by injecting NF96.2 cells into the sciatic nerve of nude mice. After tumor formation, LLS30 (10 mg/kg, once daily for 14 consecutive days) was administered intraperitoneally, and tumor burden was monitored using in vivo imaging.
Results: In the LLS30 group, tumor bioluminescence signals were significantly reduced, tumor growth was strongly inhibited, and the formation of lung metastases was almost completely suppressed. [1]
Methods: Nude mice were subcutaneously inoculated with 22RV1 cells. After tumor formation, LLS30 (30 mg/kg, daily for 2 consecutive weeks) was administered intraperitoneally, and tumor volume and body weight were monitored.
Results: LLS30 significantly inhibited tumor growth, reduced the Ki-67 positivity rate by 38.8%, and caused no significant weight loss in mice, demonstrating good safety. [2]
Chemical Properties
Molecular Weight701.47
FormulaC34H33Cl4N5O3
Cas No.2138367-58-3
SmilesO=C(N)CC(NCC1=CC=C(Cl)C(Cl)=C1)C2=CC=C3C(N=C(C=4C=CC(=CC4)N(CCO)CCO)N3CC5=CC=C(Cl)C(Cl)=C5)=C2
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Keywords

Related Tags: LLS30 chemical structure | LLS30 in vivo | LLS30 in vitro | LLS30 formula | LLS30 molecular weight